Antithrombotic and antiplatelet effects of plant-derived
compounds: a great utility potential for primary, secondary,
and tertiary care in the framework of 3P medicine

J 2022

Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine

KUBATKA, Peter, Alena MAZURAKOVA, Lenka KOKLESOVA, Marek SAMEC, Juraj SOKOL et. al.

Základní údaje

Originální název

Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine

Autoři

Vydání

EPMA JOURNAL, Cham, SPRINGER INT PUBL AG, 2022, 1878-5077

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.500

Kód RIV

RIV/00216224:14160/22:00129767

Organizační jednotka

Farmaceutická fakulta

DOI

http://dx.doi.org/10.1007/s13167-022-00293-2

UT WoS

000840590800001

Klíčová slova anglicky

Predictive preventive personalized medicine; Thrombosis; Antiplatelet effects; Anticoagulation; Circulation; Vascular disease; Ischemic stroke; Treated cancers; COVID-19; Comorbidities; Individualized patient profile; Primary; secondary; tertiary care

Štítky

rivok, ÚPL

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 4. 2023 17:00, JUDr. Sabina Krejčiříková

Anotace

V originále

Thromboembolism is the third leading vascular disease, with a high annual incidence of 1 to 2 cases per 1000 individuals within the general population. The broader term venous thromboembolism generally refers to deep vein thrombosis, pulmonary embolism, and/or a combination of both. Therefore, thromboembolism can affect both – the central and peripheral veins. Arterial thromboembolism causes systemic ischemia by disturbing blood flow and oxygen supply to organs, tissues, and cells causing, therefore, apoptosis and/or necrosis in the affected tissues. Currently applied antithrombotic drugs used, e.g. to protect affected individuals against ischemic stroke, demonstrate significant limitations. For example, platelet inhibitors possess only moderate efficacy. On the other hand, thrombolytics and anticoagulants significantly increase hemorrhage. Contextually, new approaches are extensively under consideration to develop next-generation antithrombotics with improved efficacy and more personalized and targeted application. To this end, phytochemicals show potent antithrombotic efficacy demonstrated in numerous in vitro, ex vivo, and in vivo models as well as in clinical evaluations conducted on healthy individuals and persons at high risk of thrombotic events, such as pregnant women (primary care), cancer, and COVID-19-affected patients (secondary and tertiary care). Here, we hypothesized that specific antithrombotic and antiplatelet effects of plant-derived compounds might be of great clinical utility in primary, secondary, and tertiary care. To increase the efficacy, precise patient stratification based on predictive diagnostics is essential for targeted protection and treatments tailored to the person in the framework of 3P medicine. Contextually, this paper aims at critical review toward the involvement of specific classes of phytochemicals in antiplatelet and anticoagulation adapted to clinical needs. The paper exemplifies selected plant-derived drugs, plant extracts, and whole plant foods/herbs demonstrating their specific antithrombotic, antiplatelet, and fibrinolytic activities relevant for primary, secondary, and tertiary care. One of the examples considered is antithrombotic and antiplatelet protection specifically relevant for COVID-19-affected patient groups.

Citovat

KUBATKA, Peter, Alena MAZURAKOVA, Lenka KOKLESOVA, Marek SAMEC, Juraj SOKOL, Samson Mathews SAMUEL, Erik KUDELA, Kamil BIRINGER, Ondrej BUGOS, Martin PEC, Barbara LINK, Marian ADAMKOV, Karel ŠMEJKAL, Dietrich BUSSELBERG a Olga GOLUBNITSCHAJA. Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine. EPMA JOURNAL. Cham: SPRINGER INT PUBL AG, 2022, roč. 13, č. 3, s. 407-431. ISSN 1878-5077. Dostupné z: https://dx.doi.org/10.1007/s13167-022-00293-2.

@article{2276480,
   author = {Kubatka, Peter and Mazurakova, Alena and Koklesova, Lenka and Samec, Marek and Sokol, Juraj and Samuel, Samson Mathews and Kudela, Erik and Biringer, Kamil and Bugos, Ondrej and Pec, Martin and Link, Barbara and Adamkov, Marian and Šmejkal, Karel and Busselberg, Dietrich and Golubnitschaja, Olga},
   article_location = {Cham},
   article_number = {3},
   doi = {http://dx.doi.org/10.1007/s13167-022-00293-2},
   keywords = {Predictive preventive personalized medicine; Thrombosis; Antiplatelet effects; Anticoagulation; Circulation; Vascular disease; Ischemic stroke; Treated cancers; COVID-19; Comorbidities; Individualized patient profile; Primary; secondary; tertiary care},
   language = {eng},
   issn = {1878-5077},
   journal = {EPMA JOURNAL},
   title = {Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine},
   url = {https://link.springer.com/article/10.1007/s13167-022-00293-2},
   volume = {13},
   year = {2022}
}

TY  - JOUR
ID  - 2276480
AU  - Kubatka, Peter - Mazurakova, Alena - Koklesova, Lenka - Samec, Marek - Sokol, Juraj - Samuel, Samson Mathews - Kudela, Erik - Biringer, Kamil - Bugos, Ondrej - Pec, Martin - Link, Barbara - Adamkov, Marian - Šmejkal, Karel - Busselberg, Dietrich - Golubnitschaja, Olga
PY  - 2022
TI  - Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine
JF  - EPMA JOURNAL
VL  - 13
IS  - 3
SP  - 407-431
EP  - 407-431
PB  - SPRINGER INT PUBL AG
SN  - 18785077
KW  - Predictive preventive personalized medicine
KW  - Thrombosis
KW  - Antiplatelet effects
KW  - Anticoagulation
KW  - Circulation
KW  - Vascular disease
KW  - Ischemic stroke
KW  - Treated cancers
KW  - COVID-19
KW  - Comorbidities
KW  - Individualized patient profile
KW  - Primary
KW  - secondary
KW  - tertiary care
UR  - https://link.springer.com/article/10.1007/s13167-022-00293-2
N2  - Thromboembolism is the third leading vascular disease, with a high annual incidence of 1 to 2 cases per 1000 individuals within the general population. The broader term venous thromboembolism generally refers to deep vein thrombosis, pulmonary embolism, and/or a combination of both. Therefore, thromboembolism can affect both – the central and peripheral veins. Arterial thromboembolism causes systemic ischemia by disturbing blood flow and oxygen supply to organs, tissues, and cells causing, therefore, apoptosis and/or necrosis in the affected tissues. Currently applied antithrombotic drugs used, e.g. to protect affected individuals against ischemic stroke, demonstrate significant limitations. For example, platelet inhibitors possess only moderate efficacy. On the other hand, thrombolytics and anticoagulants significantly increase hemorrhage. Contextually, new approaches are extensively under consideration to develop next-generation antithrombotics with improved efficacy and more personalized and targeted application. To this end, phytochemicals show potent antithrombotic efficacy demonstrated in numerous in vitro, ex vivo, and in vivo models as well as in clinical evaluations conducted on healthy individuals and persons at high risk of thrombotic events, such as pregnant women (primary care), cancer, and COVID-19-affected patients (secondary and tertiary care). Here, we hypothesized that specific antithrombotic and antiplatelet effects of plant-derived compounds might be of great clinical utility in primary, secondary, and tertiary care. To increase the efficacy, precise patient stratification based on predictive diagnostics is essential for targeted protection and treatments tailored to the person in the framework of 3P medicine. Contextually, this paper aims at critical review toward the involvement of specific classes of phytochemicals in antiplatelet and anticoagulation adapted to clinical needs. The paper exemplifies selected plant-derived drugs, plant extracts, and whole plant foods/herbs demonstrating their specific antithrombotic, antiplatelet, and fibrinolytic activities relevant for primary, secondary, and tertiary care. One of the examples considered is antithrombotic and antiplatelet protection specifically relevant for COVID-19-affected patient groups.
ER  -

KUBATKA, Peter, Alena MAZURAKOVA, Lenka KOKLESOVA, Marek SAMEC, Juraj SOKOL, Samson Mathews SAMUEL, Erik KUDELA, Kamil BIRINGER, Ondrej BUGOS, Martin PEC, Barbara LINK, Marian ADAMKOV, Karel ŠMEJKAL, Dietrich BUSSELBERG a Olga GOLUBNITSCHAJA. Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine. \textit{EPMA JOURNAL}. Cham: SPRINGER INT PUBL AG, 2022, roč.~13, č.~3, s.~407-431. ISSN~1878-5077. Dostupné z: https://dx.doi.org/10.1007/s13167-022-00293-2.

Podrobný výpis o publikaci